Trinity was featured in the Vault’s list of top employers for diversity, equity, and inclusion.
Trinity’s recent white paper, titled Dawn of a New Era: Evolving Needs, Solutions and Technology in U.S. HEOR, was featured in a recent article by Formulary Watch.
The U.S. health economics and outcomes research (HEOR) field has seen many changes over the last decade, including significant growth driven by payers, regulators and clinicians who are increasingly looking to Real-World Evidence (RWE) as a valuable source for patient-level data. To understand the implications of this growth, the Trinity Life Sciences Evidence Strategy team sought to gain a multi-disciplinary view on where and how HEOR experts see the field evolving and to better understand how HEOR capabilities can be…
Register now to watch our virtual issue panel or view our in-person and virtual posters – or email: email@example.com to discuss one of our presentations listed below.
Virtual Issue Panel:
Tuesday, May 17 | 4:30 pm EDT
IP14: The Challenges of Bringing Cell & Gene Therapies to Emerging Markets
A panel of experts from different markets share their experiences and perspectives about the challenges associated with the access and funding of cell and gene therapies, given the issues associated with…
Learning and Development leaders within life sciences have led and managed change like never before. The global pandemic brought live customer engagements to a halt and an intense focus on using time for enhanced development. To deliver, Learning and Development (L&D) teams had to identify resources to meet the expectations of stakeholders while redesigning and virtually-delivering to learners. In most scenarios, L&D teams were learning at the same time as their audiences.
This study assesses the current landscape of L&D,…
April 26, 2022 | 12:00 – 12:30 PM ET
Join Trinity Life Sciences for a webinar that explores the findings from our TGaS report entitled, ‘Commercial and Medical Affairs Leaders Landscape 2022’. The study is based on the responses of 35 Commercial leaders and 24 Medical Affairs leaders representing 56 separate biopharmaceutical companies.
Commercial and Medical Affairs teams continue to play an important role in healthcare innovation and the value of having cross-functional collaboration is more critical than ever.
April 8, 2022
The Assessment Process of Innovativeness of a New Medicine in Italy
In April 2017, AIFA (Agenzia Italiana del Farmaco, Italian Medicines Agency) released an upgraded algorithm to assess and evaluate the level of innovativeness of new drugs seeking reimbursement from the EUR one billion innovative medicine fund made available by the Italian MoH (Ministero della Salute, Ministry of Health).
The algorithm introduced in 2017 provides a multi-dimensional approach: innovativeness will be judged by AIFA’s CTS (Commissione Tecnico-Scientifica,…
March 29, 2022
French president Emmanuel Macron announced a two-year trial that will allow pharmaceutical products that receive an ‘Amélioration du Service Médical Rendu’ (ASMR) rating of IV or better to get reimbursement immediately after the evaluation by the Transparency Committee (TC)In these cases, price negotiations will start while the new therapies are already on the marketThis new reform started in January 2022 as part of a two-year pilot project and is expected to significantly reduce the average…
The Example of ASH 2021
Medical conferences are designed to bring bright minds together and pique interest and curiosity. The American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), European Society for Medical Oncology (ESMO), Gene Therapy for Rare Disorders, and other medical conferences play an important role in disseminating clinical and scientific information. Attendees range from physicians to investors, and the conferences provide a forum for peer-to-peer interactions, exposure to current research, innovative trends and an environment…
March 18, 2022
An analysis was conducted of all the orphan therapies registered by the FDA and ANVISA before and after 2018 to effectively evaluate approval times once the RDC 205 pathway was implemented. The main takeaways from the analysis can be found below:
The difference between FDA and ANVISA time to approval for orphan drugs is four times shorter after the implementation of the RDC 205 / 2017 pathwayThe RDC 2015 pathway regulated the deadlines for the…